OPHTHALMIC FORMULATION COMPRISING N-[5-(AMINOSULFONYL)-4-METHYL-1,3- THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)PHENYL]ACETAMIDE HEMIHYDRATE

1 . An ophthalmic formulation comprising:

a) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate,

b) polyethylene glycol, and

c) artificial tears solution, wherein the artificial tears solution contains glycerin, hypromellose, and polyethylene glycol 400 and optionally povidone.

2 . The ophthalmic formulation according to claim 1 , wherein the ophthalmic formulation has a pH value in the range of from 4.0 to 7.0.

3 . The ophthalmic formulation according to claim 1 , wherein the ophthalmic formulation has a pH value in the range of from 5.5 to 6.5.

4 . The ophthalmic formulation according to claim 1 , wherein the ophthalmic formulation has a viscosity between 25 cps and 50 cps.

5 . The ophthalmic formulation according to claim 1 , wherein the polyethylene glycol has an average molecular weight in the range of from 200 g/mol to 400 g/mol.

6 . The ophthalmic formulation according to claim 1 , wherein the polyethylene glycol is contained in the ophthalmic formulation in an amount in the range of from 40 µ g per ml ophthalmic formulation to 70 µg per ml ophthalmic formulation.

7 . The ophthalmic formulation according to claim 1 , wherein the N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]acetamide hemihydrate is contained in the ophthalmic formulation in an amount in the range of from 40 µg per ml ophthalmic formulation to 60 µg per ml ophthalmic formulation.

8 . The ophthalmic formulation according to claim 1 , wherein the artificial tears solution is contained in the ophthalmic formulation in an amount in the range of from 0.9 g per ml ophthalmic formulation to 1.3 g per ml ophthalmic formulation.

9 . The ophthalmic formulation according to claim 1 , wherein the wherein the artificial tears solution further contains carboxymethylcellulose, dextran, polysorbate, polyvinyl alcohol, povidone, propylene glycol, ascorbic acid, benzalkonium chloride, boric acid, dextrose, disodium phosphate, glycine, magnesium chloride, potassium chloride, purified water, sodium borate, sodium chloride, sodium citrate, and/or sodium lactate.

10 . The ophthalmic formulation according to claim 1 , wherein the artificial tears solution is Visine® tears solution.

11 . A method for the production of the ophthalmic formulation as defined in claim 1 , the method comprising the steps

I) providing N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-Nmethyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate,

II) providing polyethylene glycol,

III) providing artificial tears solution, wherein the artificial tears solution contains glycerin, hypromellose, and polyethylene glycol 400 and optionally povidone,

IV) preparing a stock solution of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate in polyethylene glycol,

V) diluting the stock solution with artificial tears solution until the desired concentration is reached,

VI) adjusting the pH value by addition of an aqueous solution of an acid to the desired pH value, and

VII) performing a sterial filtration by means of a suitable sterile filter to obtain the ophthalmic formulation.

12 . The method according to claim 11 , wherein the pH value is adjusted to a value in the range of from 5.5 to 6.5.

13 . The method according to claim 11 , wherein the sterile filtration is performed with a regenerated cellulose (RC) 0.2 µm filter.

14 . The method according to claim 11 , wherein the polyethylene glycol is polyethylene glycol 400 and/or the artificial tears solution is the Visine® tears solution.